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Abstract: Prostate-specific membrane antigen (PSMA) targeted PET has a high detection rate for bio-
chemical recurrence (BCR) of prostate cancer (PCa). Nevertheless, even at high prostate-specific antigen
(PSA) levels (> 3 ng/ml), a relevant number of PSMA-PET scans are negative, mainly due to PSMA-
negative PCa. Our objective was to investigate whether PSMA-expression patterns of the primary tumour
on immunohistochemistry (IHC) are associated with PSMA-PET detection rate of recurrent PCa. Meth-
ods: Retrospective institutional review board approved single-centre analysis of patients who had under-
gone 68Ga-PSMA-11-PET for BCR after radical prostatectomy (RPE) between 04/2016 and 07/2019,
with tumour specimens available for PSMA-IHC. Clinical information (age, PSA-level, ongoing androgen
deprivation therapy (ADT), Gleason score) and PSMA-IHC of the primary tumour were collected and
their relationship to results from PSMA-PET (positive/negative) was investigated using a multiple lo-
gistic regression analysis. Results: 120 PSMA-PET scans in 74 patients were available for this analysis.
Overall detection rate was 62% (74/120 scans), with a mean PSA value at scan time of 0.99 ng/ml (IQR
0.32-4.27). Of the clinical factors, only PSA-level and ADT were associated with PSMA-PET positivity.
The percentage of PSMA-negative tumour area on IHC (PSMA%neg) had a significant association to
PSMA-PET negativity (OR = 2.88, p < 0.001), while membranous PSMA-expression showed no associ-
ation (p = 0.73). The positive predictive value of PSMA%neg ฀ 50% for a negative PSMA-PET was 85%
(13/11) and for a PSMA%neg of 80% or more, 100% (9/9). Conclusions: PSMA-negative tumour area
on IHC exhibited the strongest association with negative PSMA-PET scans, beside PSA-level and ADT.
Even at very high PSA levels, PSMA-PET scans were negative in most of the patients with PSMA%neg
฀ 50%.
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Abstract 
Prostate-specific membrane antigen (PSMA) targeted PET has a high detection rate for biochemical 
recurrence (BCR) of prostate cancer (PCa). Nevertheless, even at high prostate-specific antigen (PSA) 
levels (> 3 ng/ml), a relevant number of PSMA-PET scans are negative, mainly due to PSMA-negative PCa. 
Our objective was to investigate whether PSMA-expression patterns of the primary tumour on 
immunohistochemistry (IHC) are associated with PSMA-PET detection rate of recurrent PCa. 
Methods: Retrospective institutional review board approved single-centre analysis of patients who had 
undergone 68Ga-PSMA-11-PET for BCR after radical prostatectomy (RPE) between 04/2016 and 07/2019, 
with tumour specimens available for PSMA-IHC. Clinical information (age, PSA-level, ongoing androgen 
deprivation therapy (ADT), Gleason score) and PSMA-IHC of the primary tumour were collected and 
their relationship to results from PSMA-PET (positive/negative) was investigated using a multiple logistic 
regression analysis.  
Results: 120 PSMA-PET scans in 74 patients were available for this analysis. Overall detection rate was 
62% (74/120 scans), with a mean PSA value at scan time of 0.99 ng/ml (IQR 0.32-4.27). Of the clinical 
factors, only PSA-level and ADT were associated with PSMA-PET positivity. The percentage of 
PSMA-negative tumour area on IHC (PSMA%neg) had a significant association to PSMA-PET negativity (OR 
= 2.88, p < 0.001), while membranous PSMA-expression showed no association (p = 0.73). The positive 
predictive value of PSMA%neg ≥ 50% for a negative PSMA-PET was 85% (13/11) and for a PSMA%neg of 80% 
or more, 100% (9/9). 
Conclusions: PSMA-negative tumour area on IHC exhibited the strongest association with negative 
PSMA-PET scans, beside PSA-level and ADT. Even at very high PSA levels, PSMA-PET scans were negative 
in most of the patients with PSMA%neg ≥ 50%. 










Prostate-specific membrane antigen (PSMA) is a 
type 2 integral membrane protein expressed in the 
cytoplasm of normal prostate tissue and particularly 
overexpressed on the cell membrane in prostate 
cancer (PCa) [1-4]. There is increasing evidence that 
PSMA-expression of the primary tumour is associated 
with a higher Gleason Score (GS) and a worse 
prognosis [5-10]. Recently, higher membranous 
PSMA-expression was not only associated with 
hormone resistant PCa, but also with an increase in 
defective DNA repair mutations, a further 
explanation why PSMA-expression seems to have a 
strong association to survival [9]. However, 
PSMA-expression is very heterogeneous with a 
marked inter- and intrapatient heterogeneity [1]. 
Furthermore, increasing evidence shows that even 
within the same primary tumour PSMA-expression 
can be highly variable [11]. Therefore, the association 
between PSMA-expression of primary tumour and 
metastases is still not well understood. However, it is 
reasonable to hypothesize that metastasis of patients 
with a PSMA-negative primary tumour are more 
likely to also be PSMA-negative. Interestingly, in a 
recently published paper Paschalis et al. found that 
absence of PSMA-expression in the primary lesion on 
immunohistochemistry (IHC) at diagnosis was 
associated with a lack of PSMA expression on IHC in 
the metastasis in patients with castration-resistant 
disease [9].  
PSMA expression in PCa has gained great 
importance in the past decade since PSMA binding 
tracers are increasingly used for positron emission 
tomography (PET) [12]. In patients with biochemical 
recurrence (BCR), PSMA-PET holds a high detection 
rate with an impact on disease management in around 
50% of patients [13-15]. Detection and localization of 
lesions depend on prostate-specific antigen (PSA) 
level, with patient-based detection rates of around 
50% with PSA levels ≤ 0.5 ng/ml and around 90% 
with PSA levels > 3 ng/ml [16, 17].  
According to the literature, around 5-10% of 
primary PCa are PSMA-negative on IHC [8] and 
around 10% are negative on PSMA-PET despite high 
PSA levels [18, 19]. Even though PSMA-negative 
primary PCa is associated with a better prognosis [5, 
8, 20], PSMA-negative recurrence represents a 
challenge due to false negative PSMA-PET scans. In 
some cases, after a first negative PSMA-PET, clinician 
and patient opt to postpone treatment initiation in 
attempt to localize disease in a subsequent 
examination [15, 21, 22]. Therefore, discrimination 
between negative PSMA-PET due to its limited spatial 
resolution of small tumour burden or due to PSMA- 
negative PCa could improve patient management.  
The aim of our study is to investigate whether 
the immunohistochemical PSMA expression patterns 
on IHC of the primary tumour is associated with the 
68Ga-PSMA-11-PET positivity for BCR. 
Patients and Methods 
Study population 
This retrospective single-centre cohort study 
included all consecutive patients referred to 
68Ga-PSMA-11-PET for BCR of PCa or PSA persistence 
after surgery between April 2016 and July 2019 who 
had previously undergone radical prostatectomy 
(RPE) at our institution. For patients who had had 
more than one 68Ga-PSMA-11-PET for restaging, up to 
3 scans were included per patient, including 
subsequent scans after a previously negative 68Ga- 
PSMA-11-PET and further scans because of a new rise 
in PSA value after 68Ga-PSMA-11-PET-guided 
treatment. 68Ga-PSMA-11-PET for staging PCa were 
excluded, as well as patients with prostatectomy 
specimen not available for histopathological 
evaluation. For patients with nodal metastasis found 
by pelvic lymph node dissection (pLND), the largest 
nodal metastasis was included in histopathology 
analysis. The local ethics committee approved the 
study protocol and all patients had given a general 
written informed consent for retrospective use of their 
data (BASEC Nr. 2016-01776). 
Study design 
 We collected relevant clinical data from patient’s 
charts such as PSA level at scan time, tumour 
(modified) Gleason Score (GS) / respective 
ISUP/WHO prognostic grade group [23] and 
information regarding ongoing androgen deprivation 
therapy (ADT). Prostatectomy specimens were 
analysed for PSMA expression in the primary tumour 
on IHC. We classified 68Ga-PSMA-11-PET for BCR as 
positive or negative according to the clinical reports. 
For the positive scans, maximum standard uptake 
value (SUVmax) was recorded for local recurrence and 
for the lesion with the highest SUVmax in case of 
metastasis, which were also characterized by 
localization (local lymph nodes (LN), distant LN, 
bone or visceral). 
Imaging 
Patients had undergone clinical routine 
68Ga-PSMA-11-PET/computed tomography (CT) on a 
Discovery VCT 690 PET/CT (GE Healthcare, 
Waukesha, WI, USA) or on a Discovery MI PET/CT 
(GE Healthcare, Waukesha, WI, USA) or 
68Ga-PSMA-11-PET/magnetic resonance (MR) 
(SIGNA PET/MR, GE Healthcare, Waukesha, WI, 
USA) after a single injection of 68Ga-PSMA-11 (mean 





dose ± standard deviation (SD) 130 ± 18 MBq, range 
81-171 MBq). The institutional protocol is in 
agreement with the EANM and SNMMI procedure 
guidelines [24]. Details are given in the supplements.  
Imaging analysis 
The acquired PET/CT and PET/MR images 
were analysed in a dedicated review workstation 
(Advantage Workstation, Version 4.6 or 4.7, GE 
Healthcare), which enables the review of the PET and 
the CT or MR images side by side and in fused mode. 
All scans were analysed and reported on clinical 
routine by dual board-certified radiologists and 
nuclear medicine physicians with 5-10 years of 
experience, incorporating both the MR or CT and PET 
information and being aware of 68Ga-PSMA-11-PET 
pitfalls such as neural ganglia, Paget’s disease, 
sarcoidosis and others [25, 26]. In order to correctly 
classify 68Ga-PSMA-11-PET scans as positive or 
negative the validated Prostate Cancer Molecular 
Imaging Standardized Evaluation (PROMISE) 
guidelines were used [27]. Patients with equivocal 
findings on reports were followed-up to determine 
whether lesions were true or false-positive. SUVmax 
was recorded for all local recurrence lesions as well as 
for the metastatic lesion with the highest SUVmax in 
each positive 68Ga-PSMA-11-PET. 
Radical prostatectomy and lymphadenectomy 
All RPEs were performed in form of a 
robot-assisted transperitoneal laparoscopic radical 
prostatectomy including the seminal vesicles, with 
bilateral pLND by experienced urologists at our 
institution as described earlier [28]. All operations 
were performed using the four-arm Da Vinci SI 
system (Intuitive Surgical, Inc., USA). pLND included 
the external iliac, obturator and internal iliac LN with 
an upper resection boundary defined by the crossing 
of the ureter over the common iliac artery and was 
performed in all patients selected for RPE. 
PSMA and additional staining on 
immunohistochemistry 
 One slide from the RPE specimen was chosen for 
further investigation, harbouring the largest area of 
representative tumour and therefore defining the 
dominant tumour. For the regional lymph node 
metastases (pN1) the single one or, if more than one 
was available, the largest one was chosen for further 
investigation. PSMA-IHC staining for the dominant 
tumour on the prostatectomy specimen and for the 
largest metastatic node from pLND was performed as 
described previously [29]. The predominant 
PSMA-expression patterns were visually quantified 
using a four-tiered system (0 = negative, 1+ = weak, 
2+ = moderate, 3+ = strong) for each membranous and 
cytoplasmic PSMA expression (PSMAmemb and 
PSMAcytosol) by two board certified, experienced 
genito-urinary pathologists (J.H.R, N.J.R.). Examples 
of expression patterns are shown in Figure S1 
(supplementary material). Furthermore, tumour areas 
without PSMA expression were quantified in steps of 
5%, 10% and further 10% increments in relation to the 
total tumour area, as percentage PSMA-negative 
tumour area (PSMA%neg) as a consent of both 
pathologists. Heterogeneity was defined by 
differences in the staining pattern of at least 5% of the 
representative tumour slide, in both primary tumour 
and lymph node metastasis (Figure S2, 
supplementary material).  
In selected cases, depending on the results, 
additional stainings were performed. For 
Chromogranin A staining, the LK2H10 clone (1:500, 
Cell Marque Lifescreen Ltd.) was used like previously 
described PSMA staining. For Synaptophysin staining 
the 27G12 clone (1:50, Novocastra Ltd.) and for 
Androgenreceptor the F39.4.1 clone (1:250, BioGenex) 
were used on a Leica Bond device according to 
standard protocols. Synaptophysin expression was 
visually evaluated in 1%, 5%, 10% and further 10% 
steps of expression. Predominant Androgenreceptor 
expression of the tumour was semi-quantitatively 
evaluated using a four-tiered system (0 = negative, 1+ 
= weak, 2+ = moderate, 3+ = strong). 
Statistical analysis 
Descriptive statistics were used to display 
patient data as median and interquartile range (IQR) 
with 25th and 75th percentiles (Q1-Q3), as well as 
percentages, and were performed using Excel (Excel, 
version 2016, Microsoft, USA). Data was analysed for 
normal distribution using normal probability plots. 
Correlations were done using bivariate Pearson’s 
correlation in SPSS Version 25 (IBM, Armonk, New 
York, USA) and results are presented with the 
coefficient (r), p value and confidence interval (CI). 
Receiver operating curves (ROC) were analysed using 
DeLong method in Medcalc Statistical Software 
version 18.2.1 (MedCalc Software bvba, Ostend, 
Belgium). 
Associations between 68Ga-PSMA-11-PET 
positivity and several clinical and primary tumour 
variables were assessed and investigated with 
multiple logistic regression analysis. The variables 
entered in the multiple logistic regression analysis 
were selected by a univariate analysis with a p value 
cut-off point of 0.1. All logistic regression analyses 
were performed using R (details given in the 
supplements, R version 3.6.1; R Foundation for 
Statistical computing, Vienna, Austria) and SPSS 
Version 25 (IBM, Armonk, New York, USA). A p value 





of < 0.05 was considered statistically significant. All 
tests were two-tailed. 
Results 
One hundred and sixty-three 68Ga-PSMA-11-PET 
scans from 101 patients were available. Patients or 
scans were excluded because of unavailability of 
clinical data or RPE specimens as well as the fourth 
scan of patients who already had three scans 
included. A total of 120 68Ga-PSMA-11-PET scans 
from 74 patients were available for this retrospective 
analysis. Figure 1 illustrates patient selection and 
characteristics. Interval between surgery and 
68Ga-PSMA-11-PET ranged from two months to 13 
years (median 4 years). Seven scans, in seven patients, 
were performed for PSA persistence after RPE with 
intervals from 2 to 4.2 months. In 30 patients there 
was pN1 disease on pLND. All patients were 
classified as having high-risk disease according to 
D’Amico risk score, based on initial PSA level and pT 
stage and GS after surgery. Characteristics of the 
patients at staging and at BCR are shown in Table 1.  
 
Table 1. Patient’s characteristics (n = 74). Age and PSA are 
presented in years and ng/ml, respectively. 
ISUP/WHO grade groups* (n = 74) 
1 1 (1%) 
2 6 (8%) 
3 14 (19%) 
4 24 (33%) 
5 29 (39%) 
pT stadium (n = 74) 
pT2 22 (30%) 
pT3 51 (69%) 
pT4 1 (1%) 
pN stadium (n = 74) 
pN0 44 (59%) 
pN1 30 (41%) 
At RPE (n = 74) 
Age median (IQR) 65 (60-70) 
PSA median (IQR) 12 (7-19) 
 <10 33 (45%) 
 10-20 23 (31%) 
 >20 18 (24%) 
At 68Ga-PSMA-11 PET scan time point (n = 120)** 
Age median (IQR) 69 (65-73) 
ADT 17 (14%) 
PSA median (IQR) 0.99 (0.32-4.27) 
 ≤0.5 42 (35%) 
 0.5-10 59 (49%) 
 ≥10 19 (16%) 
*from radical prostatectomy (RPE) specimen 
**34 patients had two or three 68Ga-PSMA-11 PET scans 
 
Median PSA value at scan time was 0.99 ng/ml 
(IQR 0.32-4.27, mean 8 ng/ml). Seventy-four of the 
120 (62%) 68Ga-PSMA-11-PET scans were positive. In 
10 scans (13%, 10/74), local recurrence was detected 
(median SUVmax 10.2, IQR 7.5-14.3), in 4 of them (5%, 
4/74) it was the only suspicious lesion for PCa. In 70 
scans, metastatic lesions were detected (median 
SUVmax 9.7, IQR 7.4-24.1, considering the lesion with 
the highest SUVmax). The highest SUVmax was found in 
the prostate bed in 9 scans (12%, 9/74), in nodes in 33 
scans (45%, 15 pelvic, 18 distant), in bone in 27 scans 
(36%) and in visceral organs in 5 (7%, 4 in the lungs 
and 1 peritoneal). Figure 2 (A and B) shows the 
68Ga-PSMA-11-PET detection rate according to PSA 
level and the correlation between PSA and SUVmax.  
From the 30 patients with pN1 disease (from the 
pLND), a total of 44 scans was available. Twenty-eight 
scans (64%) were positive and 16 (36%) were negative. 
All positive scans showed PSMA positive metastases 
with additional local recurrence only in one.  
PSMA-expression on IHC and additional 
staining 
Primary tumour 
Forty primary tumours (54%, 40/74) fully 
expressed PSMA (PSMA%neg = 0) and 34 showed some 
PSMA-negative area: in 25 PSMA%neg was < 50% (34%, 
25/74) and in 9 ≥ 50% (12%). The primary tumour 
showed a homogeneous PSMA expression in 25 
specimens (34%) and heterogeneous in 49 (66%). 
PSMA-expressing tumour area correlated with GS (r = 
0.243, p = 0.007, CI: 0.066, 0.420, Figure 2C) and 
intensity of PSMA expression for both PSMAcytosol (r = 
0.328, p < 0.001, CI: 0.156, 0.501) and PSMAmemb (r = 
0.583, p < 0.001, CI: 0.434, 0.731). PSMAcytosol and 
PSMAmemb had a positive correlation with each other 
(r = 0.374, p < 0.001, CI: 0.205, 0.543). 
The primary tumours from patients with PSA > 1 
ng/ml and PSMA%neg > 50% (8 scans from 5 patients) 
were re-evaluated on pathology. The morphology 
showed mixed conventional patterns (Table 2; Figure 
3), without morphological evidence of a large- or 
small cell neuroendocrine carcinoma. Also staining 
for the neuroendocrine marker Synaptophysin 
revealed only single cell reaction at a maximum of < 
5% of the tumour cells. Identical Synaptophysin 
expression patterns were obtained in a control group 
of 6 carcinomas with strong and homogenous 
PSMA-expression correlating with positive 
68Ga-PSMA-11-PET scans. 
Lymph nodes 
PSMA-expression was more homogeneous in 
LN compared to primary tumours, with 22 
homogenous (73%, 22/30) compared to only 8 
heterogeneous nodes (7%). 25 nodes (83%, 25/30) 
showed no PSMA%neg (Figure 4A). Just two nodes had 
more than 50% PSMA%neg (Figure 4B). The two lymph 
node metastases in Figure 3 were stained for 
neuroendocrine markers such as Synaptophysin and 
Chromogranin A and revealed a maximum of < 1% 
reactive cells in these stainings. A positive correlation 
was found between primary tumour and nodes for 





both PSMA%neg (r = 0.841, p < 0.001, CI: 0.731, 1) and 
PSMAmemb (r = 0.446, p = 0.002, CI: 0.146, 0.616). Table 
3 gives a patient-based comparison between 
PSMA-IHC of the primary tumour and the LN, as 
well as an overview of the positive and negative 
68Ga-PSMA-11-PET scans according to PSA level for 
these 30 patients.  
 
 
Figure 1. Patient inclusion flowchart and patient characteristics. *including salvage lymph node dissection and other treatment combinations. ADT = androgen-deprivation therapy; 
IHC = immunohistochemistry; RPE = radical prostatectomy; SBRT = stereotactic body radiation therapy; sRT = salvage radiotherapy 






Figure 2. (A) Bar chart of 68Ga-PSMA-11-PET detection rate in relation to the PSA level at scan time. (B) Boxplot of the correlation between patient PSA level at scan time 
and maximum SUVmax of 68Ga-PSMA-11-PET for the 74 positive scans (r = 0.518, p < 0.001, CI: 0.260, 0.594). (C) Boxplot of the inverse correlation between PSMA-negative 
tumour area on immunohistochemistry (PSMA%neg) and maximum ISUP/WHO grade groups of the primary tumour (r = -0.243, p < 0.007, CI: -0.066, -0.420) for all 74 patients 
included in the study. SUVmax = maximum standardized uptake value 
 
Table 2. Histopathological characteristics including androgen receptor (AR) and synaptophysin expression of the primary tumour of the 
five patients with PSA > 1 ng/ml and PSMA%neg > 50%, six patients with homogeneous primary tumours without any PSMA%neg and analysis 
for lymph nodes for AR, synapthophysin and Chromogranin A of the two patients shown in Figure 4. 
Primary Tumour     
Patient PSMA%neg Heterogeneity (+ or -) AR Synaptophysin Morphology 
Pat.14 80% + 2 single cells (<1%) fused, poorly defined glands, no cribriform 
Pat.19 80% + 2 single cells (<5%) fused, poorly defined glands, solid and single cells, cytoplasmic vacuoles, no cribriform 
Pat.31 95% + 1 0 single, acinary atypical glands, no cribriform 
Pat.59 70% + 2 single cells (<5%) fused, poorly defined glands, prominent secretions, cribriform glands (<10%) 
Pat.62 80% + 3 single cells (<1%) fused, cribriform glands (~50%), solid, single cells, partially intraductal 
Pat.5 0% - 2 single cells (<5%)  
Pat.10 0% - 1 single cells (<5%)  
Pat.29 0% - 0 0  
Pat.32 0% - 1 single cells (<1%)  
Pat.42 0% - 0 single cells (<5%)  
Pat.71 0% - 1 single cells (<5%)  
      
Lymph Node     
Patient PSMA%neg Heterogeneity (+ / -) AR Synaptophysin Chromogranin A 
Pat.55 0% - 1 single cells (<1%) single cells (<1%) 
Pat.45 90% + 3 single cells (<1%) 0 
AR = Androgenreceptor (quantified using a four-tiered system (0 = negative, 1+ = weak, 2+ = moderate, 3+ = strong); PSMA%neg = PSMA-negative tumour area 
 






Figure 3. Overview of the primary tumour of the 5 patients with PSMA%neg > 50%. (A) shows GS 4+4 = 8, poorly defined, fused glands, wide negativity for PSMA, only single cell 
expression of Synaptophysin (arrowhead) and moderate Androgenreceptor (AR) expression (Pat. 14). (B) shows GS 4+4 = 8, focal cribriform morphology in H&E and 
predominantly fused glands with secretions, focal expression of PSMA and single cell expression of Synaptophysin and moderate AR experssion (Pat. 59). (C) shows GS 4+5 = 
9, poorly defined to solid glands with cytoplsamic vacuoles, vast negativity in the PSMA staining, single cells reactive for synaptophysin and moderate AR expression (Pat. 19). (D) 
shows GS 3+3 = 6, isolated glands can be appreciated being widely negative for PSMA, with no Synaptophysin expression and weak AR reactivity (Pat. 31). (E) shows GS 4+5 = 
9, poorly defined glands and focal cribriform growth is visiable with vast negativity for PSMA, single cell Synaptophysin expression and strong AR reactivity (Pat. 62). Scale bar 100 
mu. 
 






Figure 4. Hematoxylin and eosin staining (H&E) and immunohistochemical (IHC) PSMA staining of primary tumour (PT) and metastatic lymph node (LN) from two patients who 
had LN showing a homogeneous pattern of PSMA-expression and PSMA%neg in concordance to the PT. (A) Shows a PT with GS 4+4 = 8 and 0% PSMA%neg and LN metastasis with 
GS 4+5 = 9 and 0% PSMA%neg (Pat.45). (B) Shows a primary tumour with GS 4+4 = 8 and 80% PSMA%neg and LN metastasis with GS 4+5 = 9 and 90% PSMA%neg (Pat.45). Bars 
represent 5mm with tumour outlined in blue, with exception of the bottom row which shows a magnification of PSMA-IHC images (bar 250 µm). 
 
Logistic regression analysis   
All predictors except PSA showed an 
approximately normal distribution. Since PSA 
showed a skewed distribution and suspected 
nonlinear effect has been reported [30], a log 
transformation was applied to this predictor. In the 
univariate analysis to predict negative scans (results 
given in the supplements), age, injected tracer dose 





and ISUP grade group did not reach the cut-off point 
of p = 0.1 and were, therefore, not selected for the 
multiple logistic regression. In the multiple logistic 
regression analysis, only PSA, ongoing ADT and 
PSMA%neg had an association with 68Ga-PSMA-11-PET 
detection rate. Both higher PSA values and ongoing 
ADT were associated with scan positivity yielding 
areas under the ROC curve (AUC) of 0.836 (95% CI: 
0.757-0.914, p < 0.001 / OR 0.28, p < 0.001) and 0.736 
(95% CI: 0.648-0.823, p < 0.001 / OR 0.01, p = 0.047), 
respectively. PSMA%neg of the primary tumour was 
associated with scan negativity with an AUC of 0.608 
(95% CI: 0.501-0.714, p = 0.047 / OR 2.88, p < 0.001). 
PSMAcytosol and PSMAmemb had no association with 
68Ga-PSMA-11-PET detection rate. Values for all 
variables are given in Table 4. 
 
Table 3. Patient-based comparison (n = 30) between 
PSMA-expression on IHC of primary tumours and lymph nodes. 
The right column shows an overview of positive (+) and negative 
(-) 68Ga-PSMA-11-PET scans the patient had according to PSA 
level at scan time (≤ 2 or > 2 ng/ml).  
 PSMA-cytosol* PSMA-membranous* PSMA%neg PSMA PET scan 


















Pat.1 3 1 2 2 4% 0% +  
Pat.2 3 2 3 3 0% 0% +  
Pat.4 2 2 3 3 0% 0% -  
Pat.5 2 1 3 3 0% 0%  + + 
Pat.7 2 2 3 3 0% 0% + + + 
Pat.12 2 2 2 2 20% 0% + + 
Pat.16 3 2 3 3 0% 0% -  
Pat.23 2 2 2 3 0% 0% - + +  
Pat.27 2 1 2 2 10% 0%  + 
Pat.32 2 2 3 3 0% 0%  + 
Pat.33 3 2 3 2 5% 10% +  
Pat.34 3 2 3 3 0% 0% -  
Pat.36 1 1 3 3 0% 0% +  
Pat.38 2 2 3 2 10% 10% -  
Pat.39 1 2 3 3 5% 0% -  
Pat.40 2 2 3 3 0% 0% - -  
Pat.42 2 2 3 3 0% 0%  + + 
Pat.44 2 1 2 2 0% 0% - + +  
Pat.45 2 2 2 3 80% 90% - - -  
Pat.50 3 2 3 3 0% 0% -  
Pat.51 3 2 3 3 0% 0% -  
Pat.52 3 2 3 3 5% 0% + +  
Pat.54 3 2 3 3 40% 0%  + + 
Pat.55 2 2 3 2 0% 0% +  
Pat.62 2 2 2 2 80% 70%  - 
Pat.64 2 2 2 2 0% 0%  + 
Pat.65 2 2 2 2 40% 40% + + 
Pat.69 2 2 2 3 60% 0% -  
Pat.70 3 2 2 3 0% 0% -  
Pat.71 2 2 3 3 0% 0%  + 
*quantified using a four-tiered system (0 = negative, 1+ = weak, 2+ = moderate, 3+ 
= strong) for PSMA-positive expression. IHC: immunohistochemistry. PSMA%neg: 
percentage of PSMA-negative tumour area. 
 
Correlation of PSMA%neg with 
68Ga-PSMA-11-PET positivity 
On a scan-based analysis, PSMA%neg correlated 
with scan negativity (r = 0.309, p = 0.001, CI: 0.136, 
0.482). The distribution of positive and negative 
68Ga-PSMA-11-PET scans according to PSMA%neg of 
the primary tumour and PSA level is shown in Figure 
5 (A and B). A PSMA%neg of 50% or more could predict 
a negative 68Ga-PSMA-11-PET with a positive 
predictive value (PPV) of 85% (11/13 scans were 
negative, in 9 patients). Only one patient with 
PSMA%neg of 70% had positive scans (two), in both 
scans the PSMA-positive metastases were small, 
despite high PSA values of 10.4 ng/ml and 24 ng/ml 
(Figure 5C). By increasing the threshold to 80%, PPV 
would be 100% in our sample (9/9 scans were 
negative, in 6 patients, Figure 5D and supplementary 
Figure S3), without any patient presenting with a 
positive scan. Furthermore, all patients with a PSA 
level above 2 ng/ml and less than 80% PSMA%neg had 
a positive 68Ga-PSMA-11-PET. For PSA values below 
2 ng/ml in patients with a PSMA%neg below 50%, 
scans were positive in 49% (33/68, Figure 5E) and 
negative in 51% (35/68). Nine of these 35 patients had 
a second scan, which was positive in five patients 
(median PSA: 1.32 ng/ml, IQR 1.2-3.37, Figure 5F) and 
again negative in four patients (median PSA: 0.55 
ng/ml, IQR 0.4-0.76).  
 
Table 4. Results of a multiple logistic regression model to predict 
negative PSMA PET scans 
Variable Estimate (log odds) SE p-value OR 95% CI 
(Intercept) 1.22 1.77 0.49 3.37 0.1 - 108.94 
PSMAmemb -0.29 0.58 0.61 0.75 0.24 - 2.31 
PSMAcytosol -0.73 0.53 0.17 0.48 0.17 - 1.37 
PSMA%neg (multiples of 20%) 1.06 0.02 <0.001 2.88 2.8 - 2.97 
ADT -2.31 1.16 0.047 0.1 0.01 - 0.97 
PSAlog -1.29 0.26 <0.001 0.28 0.17 - 0.46 
ADT = androgen-deprivation therapy; CI = confidence interval; OR = odds ratio; 
PSAlog = PSA transformed to a natural logarithmic scale; PSMAcytosol = 
PSMA-expression in the cytosol; PSMAmemb = PSMA-expression on the membrane; 
PSMA%neg = PSMA-negative tumour area in the primary tumour; SE = standard 
error 
 
On a patient-based analysis including only one 
scan per patient (74 scans, chosen the one with the 
highest PSA value for patients with more than one 
scan), PSMA%neg also correlated with scan negativity (r 
= 0.342, p = 0.003, CI: 0.121, 0.563). PPV for PSMA%neg 
≥ 50% and ≥ 80% was 88.8% and 100%, respectively.  
Discussion 
Investigating clinical parameters and the 
dominant lesion of the primary tumour with 
PSMA-IHC, we found that 68Ga-PSMA-11-PET 
positivity in the BCR setting of PCa is associated with 
the PSA level at scan time, ongoing ADT and 
PSMA%neg of the primary tumour.  






Figure 5. (A) Distribution of 68Ga-PSMA-11-PET scans according to primary tumour PSMA-negative tumour area (PSMA%neg) on immunohistochemistry (IHC) and patient 
prostate-specific antigen (PSA) level at scan time. PSMA%neg is presented on linear scale and PSA level on logarithmic scale. Patients with a PSMA%neg of 80% or more always had 
negative 68Ga-PSMA-11-PET scans, regardless of PSA levels. Patients with a PSMA-negative tumour area < 80% and a PSA level ≥ 2 ng/ml always had positive 68Ga-PSMA-11-PET 
scans. (B) Detail from figure A magnifying on scans from patients with low PSMA%neg and low PSA values. (C-F) H&E (top left) and PSMA-IHC (top middle and magnification on 
top right) of the primary tumour and lymph nodes (only in figure E, middle row), as well as 68Ga-PSMA-11-PET images (maximum intensity projection (MIP), fused PET/CT or 
PET/MR and CT or MR) of the patients who had scans marked with the respective letters in figures A or B. MIP images are in the same intensity as the fused PET images. In the 
histopathology images, bars represent 5mm with tumour outlined in blue and 250 µm in the magnification of the PSMA-IHC: (C) Primary tumour (pT3b, GS 4+4 = 8) of a 57 y.o. 
patient with 70% PSMA%neg. 68Ga-PSMA-11-PET performed for biochemical recurrence at a PSA level of 10.4 ng/ml shows only two retroperitoneal lymph nodes with 7mm 
(arrowhead, SUVmax 7.4) and 5mm (not shown). The patient received radiotherapy (RT), with a partial drop of PSA and an immediate further rise, allowing the hypothesis that 





68Ga-PSMA-11-PET underestimated disease. (D) Primary tumour (pT2c, GS 4+4 = 8) of a 68 y.o. patient with 80% PSMA%neg. The patient had two negative 68Ga-PSMA-11-PET 
scans for biochemical recurrence under PSA levels of 4.65 ng/ml and 20.36 ng/ml, respectively, and refused treatment. A third 68Ga-PSMA-11-PET scan was performed under a 
PSA level of 72 ng/ml and showed a new sclerotic lesion in the sacrum (arrowhead), suspicious for metastasis in the clinical context despite missing PSMA-expression, and 
confirmed by MR (supplementary Figure S3) which showed also multiple lesions in the vertebral spine and iliac bones. (E) Primary tumour (pT3a, GS 4+3 = 7) and a metastatic 
lymph node (LN) of a 64 y.o patient with 5% and 0% PSMA%neg, respectively. 68Ga-PSMA-11-PET performed for biochemical recurrence under a PSA level of 0.11 ng/ml with two 
small retroperitoneal nodes (SUVmax 7.8, pointed by the arrowhead, and 6.2, not shown). The patient underwent RT for the paraortal lymphatic chain achieving an undetectable 
PSA until last follow up. (F) Primary tumour (pT3b, GS 4+4 = 8) of a 64 y.o. patient with 0% PSMA%neg. 68Ga-PSMA-11-PET was negative despite a PSA of 1.69 ng/ml (only MIP 
shown). Patient underwent PSA follow-up and a second scan was performed when PSA level achieved 4.63 ng/ml, showing local recurrence in the seminal vesicles bed (blue 
arrowhead, SUVmax 7.3). 
Indeed, in patients with PSA values above 1 
ng/ml and a dominant PSMA%neg of 50% or more, 
68Ga-PSMA-11-PET were either negative or likely 
underestimating the tumour burden as shown in 
Figure 5C, where two small lymph nodes were the 
only PSMA-positive findings at a PSA of 10.4 ng/ml. 
None of these tumours showed neuroendocrine 
differentiation.  
PSMA-negativity is not an established IHC 
parameter for prostate cancer yet. However, the 
importance of prostate cancer heterogeneity and the 
high correlation between more than 50% positive 
tumour cells on PSMA-IHC with SUVmax of the 
primary tumour on 68Ga-PSMA-PET imaging has 
already been shown by Woythal et al [31]. Our results 
suggest that this correlation between PSMA%neg of the 
primary tumour with 68Ga-PSMA-PET imaging is 
maintained for metastasis in the BCR setting. In our 
cohort, the simple grading of intensity of 
membranous or cytosolic PSMA-expression was not 
associated with 68Ga-PSMA-11-PET positivity.  
Several studies investigated potential clinical 
factors to predict a positive PSMA-PET for BCR. The 
best predictive factors reported so far are PSA level 
and ADT [16], which we could confirm as the only 
clinical parameters associated with PSMA-PET 
positivity in our cohort. However, even in patients 
with high PSA levels, the rate of positive PSMA-PET 
scans of around 90% probably implies that around 
10% of PCa are PSMA-negative [16], without any 
clinical factor that can predict this.  
Interestingly, molecular analysis of primary and 
recurrent PCA by Paschalis et al. also showed that the 
PSMA expression seems to be higher in lesions after 
ADT [9], which has also been confirmed with in vitro 
studies [32]. Therefore, we believe that a combination 
of clinical parameters (PSA level and ADT) with 
quantitative PSMA-IHC of the primary tumour could 
be used to prevent repeated negative PSMA-PET 
scans. 
Given that PCa can be a heterogeneous disease, 
and that PSMA-expression is associated with more 
aggressive PCa histology, it seems reasonable to not 
exclude patients from a first PSMA-PET scan for BCR. 
As in our cohort a patient with PSMA%neg of 60% had a 
metastatic lymph node with PSMA%neg of 0% (Pat.69 
in Table 3), there is evidence by others that primary 
tumour and metastasis are not always concordant 
regarding PSMA-expression [1, 11, 33]. Nevertheless, 
in patients who underwent RPE and had a first 
negative PSMA-PET performed for BCR, a high 
PSMA%neg of the primary tumour is reducing the 
probability of PSMA-PET positivity. This limits the 
justification to further postpone blind salvage 
radiation in the hope to localize disease on later 
PSMA-PET scans, especially in patients with PSA 
levels of 1 ng/ml or more, as shown in Figure 5A-B. 
Of note is that the correlation between higher 
aggressiveness of tumour lesions and high PSMA 
expression is not correct in every stage of the disease. 
Results from the LuPSMA trial showed that in late 
stage castration-resistant prostate cancer patients with 
PSMA-negative, FDG-positive lesions did worse [34].  
In this regard, PSMA-IHC analysis of the 
primary tumour might be an interesting tool to learn 
more about the specific disease of an individual 
patient and to evaluate the potential of PSMA-PET on 
a personal base. This might improve the 
individualized disease approach and avoid further 
negative scans. 
The low number of primary tumours with 
significant PSMA-negative areas (9 patients with 
PSMA%neg ≥ 50%) is the main limitation of our study. 
Therefore, it was not possible to give a definitive 
optimal threshold of percentage of PSMA%neg for the 
likelihood of a negative 68Ga-PSMA-11-PET, which 
would have to be assessed in future studies with 
larger number of patients. The use of both PET/CT 
and PET/MR might have introduced some bias in the 
SUVmax measures as there is some variability among 
different PET scanners [35], though we believe it 
would not substantially affect the results or alter our 
conclusion. The use of 68Ga-PSMA-11 that is excreted 
over the kidneys might also be a potential limitation 
for PET/CT, evaluation of local recurrence. This was 
minimized with the use of diuretics. Furthermore, 
immediate applicability of our results is limited by the 
lack of assessment of PSMA-expression in clinical 
routine in prostatectomy specimens and, therefore, 
more research needs to be done to standardize the 
evaluation of PSMA%neg. However, the future 
potential of semiautomatic assessment of IHC with 
digital pathology will increase the possibility to 
incorporate these molecular parameters into decision 
making for patient selection.  






PSMA-negative tumour area of the primary 
tumour is associated with negative PSMA-PET scans 
for BCR. The integration of quantitative 
PSMA-expression based on the molecular pathology 
of the primary tumour with clinical parameters (PSA 
and ADT) has the potential to improve the patient 
selection and avoid further negative PET scans.  
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